Navigation Links
MedQuist Announces Additions to Board of Directors
Date:9/4/2008

MOUNT LAUREL, N.J., Sept. 4 /PRNewswire-FirstCall/ -- MedQuist Inc. (Nasdaq: MEDQ) today announced that its board of directors has elected John F. Jastrem, Colin J. O'Brien, and Andrew Vogel to join the board, effective September 4, 2008. Prior to the election of the new directors, the board of directors expanded the size of the board from seven to 10 members.

According to MedQuist Chairman of the Board Robert Aquilina, "We are pleased to have this opportunity to further enhance the quality and experience on the board. John, Colin and Andrew were identified as well-qualified and independent director candidates with a wide breadth of work experience. We welcome these new members and their input, and we believe they will be a tremendous asset to our board."

John F. Jastrem, 53, has been president and CEO of Exhibitgroup/Giltspur ("EG"), a division of Viad Corp. (NYSE: VVI), since 2006. EG is an industry leader in experience marketing, specializing in exhibit design, production and program management. Previously, he was an executive for eight years with Omnicom Group Inc., the world's largest advertising and marketing services company. He started with Omnicom in 1998 as chairman and CEO of Rapp Collins Worldwide-Dallas ("RCW"), the global leader in direct response marketing and database management. Prior to his tenure at Omnicom, he was president and CEO of TEAM Consultants, which specialized in strategic planning, financing, interim management, technology-enabled solutions, and mergers and acquisitions. Previously, he served as a member of the executive team at Knapp Communications Corporation (the publisher of Architectural Digest and Bon Appetit magazines), and at Wickes Companies Inc., an international retailer and manufacturer. He started his career with Andersen LLP, where he earned his CPA.

Colin J. O'Brien, 69, has been retired since 2001. He was employed in various positions with Xerox Corporation from 1992-2001, including vice president of Business Development and Systems Strategy, CEO of Xerox's New Enterprise Board, and executive chairman of XESystems Inc., a subsidiary of Xerox. In 1986, Mr. O'Brien formed an investment company with E.M. Warburg Pincus & Co. Inc., making a number of acquisitions in defense electronics. Prior to that time, he served as chairman and chief executive of Times Fiber Communications Inc., a publicly traded company, and president of General Instrument's cable television operations. He has held management positions with Union Carbide in both Canada and Europe, and has served on a number of public and private boards.

Andrew Vogel, 35, is a Managing Member of ZM Capital, a media-focused private equity firm, and has been working at ZelnickMedia Corp. since late 2003. He is an accomplished private equity investor with experience in several industries and geographic markets. Prior to joining ZelnickMedia, he was an investment professional at Ripplewood Holdings ("Ripplewood"), a private equity firm with several billion dollars of capital under management. Previously, he was an associate at McCown De Leeuw & Co., a private equity firm specializing in leveraged build-ups, and an investment banker in Lehman Brothers' Mergers and Acquisitions group. Mr. Vogel is a director of ThinkMap Inc.

About MedQuist:

MedQuist is the largest Medical Transcription Service Organization (MTSO) in the world, and a leader in technology-enabled clinical documentation workflow. MedQuist's enterprise solutions -- including mobile voice capture devices, speech recognition, Web-based workflow platforms, and global network of medical editors -- help healthcare facilities improve patient care, increase physician satisfaction, and lower operational costs. For more information, please visit http://www.medquist.com.

"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this press release regarding MedQuist's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual outcomes and results may differ materially from what is expressed or forecasted in forward-looking statements. As a result, forward-looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE MedQuist Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedQuist and StructuRad Form Partnership to Integrate Report Macros into SpeechQ for Radiology(TM)
2. MedQuist Reports First Quarter 2008 Results
3. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
4. Martek Announces Third Quarter 2008 Financial Results
5. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
6. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
7. American Oriental Bioengineering Announces Participation in September Investor Conferences
8. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
9. Mindray Medical International Announces Second Quarter 2008 Results
10. BioMS Medical announces its intention to renew a normal course issuer bid
11. Exosome Diagnostics Announces Additions to Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
(Date:3/23/2017)... 23, 2017  Agriculture technology company Cool Planet has ... note conversion to commercialize its Cool Terra and Cool ... developing products that are simultaneously profitable as well as ... last 18 months. This latest round of funding was ... The company,s primary product, Cool Terra, ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
Breaking Biology Technology:
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/20/2017)... , March 20, 2017 At this year,s CeBIT ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together ... is this year,s CeBIT partner country. At the largest German biometrics company ... use: fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
Breaking Biology News(10 mins):